Modern management of prosthetic valve anticoagulation

Mayo Clinic Proceedings

Volumn 73, Issue 7, 1998, Pages 665-680

  Tiede, Daniel J ^a,d   Nishimura, Rick A ^a,b   Gastineau, Dennis A ^a,c   Mullany, Charles J ^a   Orszulak, Thomas A ^a,d   Schaff, Hartzell V ^a  

^a Division of Cardiovascular Diseases and Internal Medicine   (United States)

^b Division of Hematology and Internal Medicine   (United States)

^c Division of Cardiovascular Surgery   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANTICOAGULATION; DIET; HEART VALVE PROSTHESIS; HUMAN; PEROPERATIVE CARE; PREGNANCY; REVIEW; SHEAR STRESS; THEORY; VALVULAR HEART DISEASE;

EID: 0031750343     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(11)64893-3     Document Type: Review

References (170)

1. Stein PD, Collins JJ Jr, Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 1986;89(Suppl 2):46S-53S
2. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992;102(Suppl 4):445S-455S
3. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves [published erratum appears in Chest 1996;109:592]. Chest 1995;108(Suppl 4):371S-379S
4. Butchart EG. Thrombogenicity, thrombosis, and embolism. In: Butchart EG, Bodnar E, editors. Current Issues in Heart Valve
5. Disease: Thrombosis, Embolism and Bleeding. London: ICR Publishers; 1992. pp 172-205
6. Yoganathan AP, Wick TM, Reul H. Influence of flow characteristics of prosthetic valves on thrombus formation. In: Butchart EG, Bodnar E, editors. Current Issues in Heart Valve Disease: Thrombosis, Embolism and Bleeding. London: ICR Publishers; 1992. pp 123148
7. Grunkemeier GL, Starr A, Rahimtoola SH. Prosthetic heart valve performance: long-term follow-up. Curr Probl Cardiol 1992;17:329406
8. Rajah SM, Sreeharan N, Joseph A, Watson DA. Prospective trial of dipyridamole and warfarin in heart valve patients [abstract]. Acta Thera (Brussels) 1980:6:54
9. Wright IS, Beck DF, Marple CD. Myocardial infarction and its treatment with anticoagulants: summary of findings in 1031 cases. Lancet 1954:1:92-95
10. Bevilacqua MP, Gimbrone MA Jr. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987;13:425-433
11. DiSesa VJ, Collins JJ Jr, Cohn LH. Hématologie complications with the St. Jude valve and reduced-dose Coumadin. Ann Thorac Surg 1989:48:280-283
12. Bernstein EF. Certain aspects of interfacial phenomena-red blood cells. FedProc 1971:30:1510-1515
13. Cella G, Schivazappa L, Casonato A, Molaro LG, Girolami A, Westwick J, et al. In vivo platelet release reaction in patients with heart valve prosthesis. Haemostasis 1980;9:263-275
14. Pumphrey CW, Dawes J. Elevation of plasma beta-thromboglobulin in patients with prosthetic cardiac valves. Thromb Res 1981:22:147-155
15. Pumphrey CW, Dawes J. Platelet alpha granule depletion: findings in patients with prosthetic heart valves and following cardiopulmonary bypass surgery. Thromb Res 1983:30:257-264
16. Ramstack JM, Zuckerman L, Mockros LF. Shear-induced activation of platelets. J Biomech 1979;12:113-125
17. Edmunds LH Jr. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987;44:430-445
18. Kasahara T. Clinical effect of dipyridamole ingestion after prosthetic heart valve replacement-especially on the blood coagulation system. Nippon Kyobu Geka Gakkai Zasshi 1977;25:1007-1021
19. Wurzinger U, Opitz R, Blasberg P, Eschweiler H, Schmid-Schönbein H. The role of hydrodynamic factors in platelet activation and thrombotic events: the effects of shear stress of short duration. In: Schettler G, Nerem RM, Schmid-Schönbein H, Mörl H, Diehm C, editors. Fluid Dynamics as a Localizing Factor for Atherosclerosis. Berlin: Springer-Verlag; 1983. pp 91-102
20. Mustard JF, Packham MA, Kinlough-Rathbone RL. Mechanisms in thrombosis. In: Bloom AL, Thomas DP, editors. Haemostasis and Thrombosis. 2nd ed. Edinburgh: Churchill Livingstone; 1987. pp 618-650
21. McDonagh J. Structure and function of factor XIII. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis. 2nd ed. Philadelphia: Lippincott; 1987. pp 289-300
22. Mosher DF. Fibronectin-relevance to hemostasis and thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis. 2nd ed. Philadelphia: Lippincott; 1987. pp 210-218
23. Lawler J. The structural and functional properties of thrombospondin. Blood 1986;67:1197-1209
24. Vermylen J, Verstraete M, Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 1986;8(Suppl B):2B-9B
25. Francis JL. The detection and measurement of factor VIII activity: a review. Med Lab Sei 1980;37:137-147
26. Madras PN, Thomson CL, Johnson WR. The effect of Coumadin upon thrombus forming on foreign surfaces. Artif Organs 1980:4:192-198
27. Yasaka M, Miyatake K, Mitani M, Beppu S, Nagata S. Yamaguchi T, et al. Intracardiac mobile thrombus and D-dimer fragment of fibrin in patients with mitral stenosis. Br Heart J 1991;66:22-25
28. Roberts WC, Morrow AG. Late postoperative pathological findings after cardiac valve replacement. Circulation 1967;35(Suppl 1):I48162
29. Bjork VO, Wilson GJ, Sternlieb JJ, Kaminsky DB. The porous metalsurfaced heart valve: long-term study without long-term anticoagulation in mitral position in goats. J Thorac Cardiovasc Surg 1988;95:1067-1082
30. Yoganathan AP, Reamer HH, Corcoran WH, Harrison EC, Shulman IA, Parnassus W. The Starr-Edwards aortic ball valve: flow characteristics, thrombus formation, and tissue overgrowth. Artif Organs 1981;5:6-17
31. Reitz BA, Stinson EB, Griepp RB, Shumway NE. Tissue valve replacement of prosthetic heart valves for thromboembolism. Am J Cardiol 1978:41:512-515
32. Metzdorff MT, Grunkemeier GL, Pinson PW, Starr A. Thrombosis of mechanical cardiac valves: a qualitative comparison of the silastic ball valve and the tilting disc valve. J Am Coll Cardiol 1984;4:5053
33. Acar J, Vahanian A, Dorent R, Fauchet M, Mundler 0, Michel PL, et al. Detection of prosthetic valve thrombosis using inindium platelet imaging. Eur Heart J 1990:11:389-398
34. Acar J, Enriquez-Sarano M, Fa rah E, Kassab R, Tubiana P, Roger V. Recurrent systemic embolie events with valve prosthesis. Eur Heart J 1984;5(Suppl D):33-38
35. Fernandez J, Samuel A, Yang SS, Sumathisena, Gooch A, Maranhao V, et al. Late thrombosis of the aortic Bjork-Shiley prosthesis: its clinical recognition and management. Chest 1976;70:12-16
36. Copans H, Lakier JB, Kinsley RH, Colsen PR, Fritz VU, Barlow JB. Thrombosed Bjork-Shiley mitral prostheses. Circulation 1980:61:169-174
37. Balram A, Kaul U, Rama Rao BV, lyers KS, Rajani M, Rao IM, et al. Thrombotic obstruction of Bjork-Shiley valves-diagnostic and surgical considerations. Int J Cardiol 1984;6:61-73
38. Nunez L, Iglesias A, Sotillo J. Entrapment of leaflet of St. Jude Medical cardiac valve prostheses by miniscule thrombus: report of two cases. Ann Thorac Surg 1980:29:566-569
39. Commerford PJ, Lloyd EA, De Nobrega JA. Thrombosis of St. Jude Medical cardiac valve in the mitral position. Chest 1981:80:326327
40. Prabhu S, Friday KJ, Reynolds D, Elkins R, Lazzara R. Thrombosis of aortic St. Jude valve. Ann Thorac Surg 1986;41:332-333
41. Deuvaert FE, Le Clerc JL, Primo G, Wellens F, De Paepe J, Van Nooten G, et al. Thrombosis of the St. Jude Medical valve prosthesis in the aortic position: a diagnostic and surgical emergency. J Cardiovasc Surg 1986:27:622-624
42. Bonchek LI, Braunwald NS. Modification of thrombus formation on prosthetic heart valves by the administration of low molecular weight dextran. Ann Surg 1967:165:200-205
43. Hodam R, Starr A, Herr R, Pierie WR. Early clinical experience with cloth-covered valvular prostheses. Ann Surg 1969:170:471-482
44. Starr A, Bonchek LI, Anderson RP, Wood JA, Chapman RD. Late complications of aortic valve replacement with cloth-covered, composite-seat prosthesis: a six-year appraisal. Ann Thorac Surg 1975:19:289-300
45. Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic StarrEdwards prostheses: a 10-19-year follow-up. Circulation 1982; 66(Suppl 1):I157-I161
46. Duvoisin GE, Brandenburg RO, McGoon DC. Factors affecting thromboembolism associated with prosthetic heart valves. Circulation 1967;35(Suppl 1):I70-I76
47. Yeh TJ, Anabtawi IN, Cornett VE, Ellison RG. Influence of rhythm and anticoagulation upon the incidence of embolization associated with Starr-Edwards prostheses. Circulation 1967;35(Suppl 1):I77181
48. Gadboys HL, Litwak RS, Niemetz J, Wisch N. Role of anticoagulants in preventing embolization from prosthetic heart valves. JAMA 1967:202:282-286
49. Bjork VO, Henze A. Management of thrombo-embolism after aortic valve replacement with the Bjork-Shiley tilting disc valve: medicamental prevention with dicumarol in comparison with dipyridamole-acetylsalicylic acid; surgical treatment of prosthetic thrombosis. Scand J Thorac Cardiovasc Surg 1975:9:183-191
50. Larsen GL, Alexander JA, Stanford W. Thromboembolic phenomena in patients with prosthetic aortic valves who did not receive anticoagulants. Ann Thorac Surg 1977:23:323-326
51. Limet R, Lepage G, Grondin CM. Thromboembolic complications with the cloth-covered Starr-Edwards aortic prosthesis in patients not receiving anticoagulants. Ann Thorac Surg 1977;23:529533
52. Moggio RA, Hammond GL, Stansel HC Jr, Glenn WW. Incidence of emboli with cloth-covered Starr-Edwards valve without anticoagulation and with varying forms of anticoagulation: analysis of 183 patients followed for 3V2 years. J Thorac Cardiovasc Surg 1978; 75:296-299
53. Thomsen PB, Alstrup P. Thromboembolism in patients without anticoagulants after aortic valve replacement with the Lillehei-Kaster disc valve. Thorac Cardiovasc Surg 1979:27:313-315
54. Ribeiro PA, AI Zaibag M, Idris M, AI Kasab S, Davies G, Mashat E, et al. Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude Medical aortic prosthesis in patients with rheumatic heart disease. J Thorac Cardiovasc Surg 1986;91:92-98
55. Hartz RS, LoCicero J III, Kucich V, DeBoer A, O'Mara S, Meyers SN, et al. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position. J Thorac Cardiovasc Surg 1986;92:684-690
56. Myers ML, Lawrie GM, Crawford ES, Howell JF, Morris GC Jr, Glaeser DH, et al. The St. Jude valve prosthesis: analysis of the clinical results in 815 implants and the need for systemic anticoagulation. J Am Coll Cardiol 1989;13:57-62
57. Effler DB, Favalora R, Groves LK. Heart valve replacement: clinical experience. Ann Thorac Surg 1965;l:4-24
58. Stein DW, Seiden R, Starr A. Thrombotic phenomena with nonanticoagulated, composite-strut aortic prostheses. J Thorac Cardiovasc Surg 1976;71:680-684
59. Forman R, Beck W, Barnard CN. Results of valve replacement with the Lillehei-Kaster disc prosthesis. Am Heart J 1977;94:282-286
60. Link KP. The discovery of dicoumarol and its sequels. Circulation 1959;19:97-107
61. Kopf GS, Hammond GL, Geha AS, Elefteriades J, Hashim SW. Long-time performance of the St. Jude Medical valve: low incidence of thromboembolism and hemorrhagic complications with modest doses of warfarin. Circulation 1987;76(Suppl 3):III132111136
62. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2. Oral anticoagulants [published erratum appears in Circulation 1995;91:A55-A56]. Circulation 1994;89:1469-1480
63. Loeliger EA, International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985:53:155-156
64. Hirsh J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants [published erratum appears in Chest 1989:96:962]. Chest 1989 Feb;95(Suppl):5S-llS
65. Hirsh J, Deykin D, Poller L. Therapeutic range for oral anticoagulant therapy. Chest 1986 Feb;89(Suppl):llS-15S
66. Stein PD, Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 1989 Feb;95(Suppl):107S-117S
67. Altman R, Rouvier J, Gurfinkel E, D'Ortencio 0, Manzanel R, de La Fuente L, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991:101:427-431
68. Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990:322:428-432
69. Butchart EG, Lewis PA, Bethel JA, Breckenridge IM. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors: recommendations for the Medtronic Hall valve. Circulation 1991;84(Suppl 3):III61-III69
70. Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude Medical prostheses. J Mean Valve Dis 1993;2:291-301
71. Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242-1245
72. Acar J. Low-dose versus standard-dose anticoagulation for prosthetic heart valves. Circulation 1995;92:2360
73. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N EnglJ Med 1995:333:1117
74. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239
75. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990:323:15051511
76. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355
77. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published erratum appears in N Engl J Med 1993:328:148]. N Engl J Med 1992:327:14061412
78. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175179
79. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990;322:863-868
80. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527-539
81. Huber KC, Gersh BJ, Bailey KR, Schaff HV, Hodge DO, Cha RH, et al. Variability in anticoagulation control predicts thromboembolism after mechanical cardiac valve replacement: a 23-year populationbased study. Mayo Clin Proc 1997:72:1103-1110
82. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995:333:5-10
83. Fihn SD. Aiming for safe anticoagulation [editorial]. N Engl J Med 1995:333:54-55
84. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983:51:15371541
85. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993:329:524-529
86. Gohlke-Barwolf C, Acar J, Burckhardt D, Oakley C, Butchart E, Krayenbuhl P, et al (Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology). Guidelines for prevention of thromboembolic events in valvular heart disease. J Heart Valve Dis 1993;2:398-410
87. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 1986;8(Suppl B):41B-56B
88. Acar J, Michel PL, Cormier B, Vahanian A, lung B. Features of patients with severe mitral stenosis with respect to atrial rhythm: atrial fibrillation in predominant and tight mitral stenosis. Acta Cardiol 1992:47:115-124
89. Chen YT, Kan MN, Chen JS, Lin WW, Hwang DS, Chang M, et al. Contributing factors to formation of left atrial spontaneous echo contrast in mitral valvular disease. J Ultrasound Med 1990;9:151155
90. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964;1:1209-1212
91. Abernathy WAS, Willis PW. Thromboembolic complications of rheumatic heart disease. Valvular Heart Dis 1973;5:132
92. Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J 1970;32:2634
93. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Med 1992;116:l-5
94. Daley R, Mattingly TW, Holt CL, Bland EF, While PD. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951;42:566-581
95. Chesebro JH, Fuster V, Danielson GK, Pluth JR, Orszulak TA, Piehler JM, et al. Time-related and chronic risk of thromboembolism after bioprosthetic valve replacement [abstract]. Circulation 1985;72(Suppl 3):lll-209
96. Heras M, Chesebro JH, Fuster V, Denny WJ, Grill PE, Bailey KR, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-1119
97. Hetzer R, Topalidis T, Borst HG. Thromboembolism and anti coagulation after isolated mitral replacement with porcine heterografts. In: Cohn LH, Gallucci V, editors. Cardiac Bioprostheses: Proceedings of the Second International Symposium. New York: Yorke Medical Books; 1982. pp 170-172
98. Oyer PE, Stinson EB, Griepp RB, Shumway NE. Valve replacement with the Starr-Edwards and Hancock prostheses: comparative analysis of late morbidity and mortality. Ann Surg 1977;186:301309
99. lonescu Ml, Smith DR, Hasan SS, Chidambaram M, Tandon AP. Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement. Ann Thorac Surg 1982;34:265277
100. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-641
101. Butchart EG. Thrombogenesis and its management. In: Acar J, Bodnar E, editors. Textbook of Acquired Heart Valve Disease. Vol 2. London: ICR Publishers; 1994. pp 1048-1120
102. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-1511
103. Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves: subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976;92:162167
104. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves: a prospective study. Am Heart J 1978;96:163165
105. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses: observations in 180 operations. JAMA 1978:239:738-739
106. Taberner DA, Poller L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus lowdose heparin in prophylaxis of deep vein thrombosis. BMJ 1978:1:272-274
107. Francis CW, Pellegrini VD Jr, Leibert KM, Totterman S, Azodo MV, Harris CM, et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 1996:75:706-711
108. Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983:249:374-378
109. Glover JJ, Morrill GB. Conservative treatment of overanticoagulated patients. Chest 1995;108:987-990
110. Madura JA, Rookstool M, Wease G. The management of patients on chronic Coumadin therapy undergoing subsequent surgical procedures. Am Surg 1994;60:542-546
111. De La Rubia J, Grau E, Montserrat I, Zuazu I, Paya A. Anaphylactic shock and vitamin Kl [letter]. Ann Intern Med 1989:110: 943
112. Reuter HD. Vitamins. In: Dukes MNG, Beely L, editors. Side Effects of Drugs, Annual 12. Amsterdam: Elsevier; 1988. pp 326331
113. Florholmen J, Waldum H, Nordoy A. Cerebral thrombosis in two patients with malabsorption syndrome treated with vitamin K. BMJ 1980:281:541
114. Rich EC, Drage CW. Severe complications of intravenous phytonadione therapy: two cases, with one fatality. Postgrad Med 1982 Nov;72:303-306
115. Mclntyre H. Management, during dental surgery, of patients on anticoagulants. Lancet 1966;2:99-100
116. Robinson GA, Nylander A. Warfarin and cataract extraction. Br J Ophthalmol 1989;73:702-703
117. McCormack P, Simcock PR, Tullo AB. Management of the anticoagulated patient for ophthalmic surgery. Eye 1993:7:749750
118. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17
119. Shaper AI. The hypercoagulable states. Ann Intern Med 1985;102:814-828
120. Limet R, Grondin CM. Cardiac valve prostheses, anticoagulation, and pregnancy. Ann Thorac Surg 1977:23:337-341
121. Lutz DJ, Noller KL, Spittel JA Jr, Danielson GK, Fish CR. Pregnancy and its complications following cardiac valve prostheses. Am J Obstet Gynecol 1978:131:460-468
122. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980:68:122140
123. Salazar E, Zajarias A, Gutierrez N, Iturbe I. The problem of cardiac valve prostheses, anticoagulants, and pregnancy. Circulation 1984;70(Suppl 1):I169-I177
124. Hanania G, Thomas D, Michel PL, Garbarz E, Age C, Millaire A, et al. Pregnancy and prosthetic heart valves: a French cooperative retrospective study of 155 cases. Eur Heart J 1994:15:16511658
125. Salazar E, Izaguirre R, Verdejo J, Mutchinick 0. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. JAm Coll Cardiol 1996:27:1698-1703
126. Lee CN, Wu CC, Lin PY, Hsieh FJ, Chen HY. Pregnancy following cardiac prosthetic valve replacement. Obstet Gynecol 1994;83: 353-356
127. Pavankumar P, Venugopal P, Kaul U, lyer KS, Das B, Sampathkumar A, et al. Pregnancy in patients with prosthetic cardiac valve: a 10-year experience. Scand J Thorac Cardiovasc Surg 1988:22:19-22
128. Sareli P, England MJ, Berk MR, Marcus RH, Epstein M, Driscoll J, et al. Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prostheses. Am J Cardiol 1989:63:1462-1465
129. Larrea JL, Nunez L, Reque JA, Gil Aguado M, Matarros R, Minguez JA. Pregnancy and mechanical valve prostheses: a high-risk situation for the mother and the fetus. Ann Thorac Surg 1983:36:459463
130. Iturbe-Alessio I, Fonseca MC, Mutchinik 0, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986:315:1390-1393
131. Lee PK, Wang RY, Chow JS, Cheung KL, Wong VC, Chan TK. Combined use of warfarin and adjusted subcutaneous heparin during pregnancy in patients with an artificial heart valve. J Am Coll Cardiol 1986:8:221-224
132. Ayhan A, Yapar EG, Yuce K, Kisnisci HA, Nazi! N, Ozmen F. Pregnancy and its complications after cardiac valve replacement. Int J Gynaecol Obstet 1991:35:117-122
133. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J 1994:71:196-201
134. Oakley CM. Anticoagulation and pregnancy. Eur Heart J 1995:16:1317-1319
135. Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annu Rev Med 1989:40:79-86
136. Chen WW, Chan CS, Lee PK, Wang RY, Wong VC. Pregnancy in patients with prosthetic heart valves: an experience with 45 pregnancies. QJM 1982:51:358-365
137. Ben Ismail M, Abid F, Trabelsi S, Taktak M, Fekih M. Cardiac valve prostheses, anticoagulation, and pregnancy. Br Heart J 1986:55:101-105
138. Born D, Martinez EE, Almeida PA, Santos DV, Carvalho AC, Moron AF, et al. Pregnancy in patients with prosthetic heart valves: the effects of anticoagulation on mother, fetus, and neonate. Am Heart J 1992:124:413-417
139. Cotrufo M, de Luca TS, Calabro R, Mastrogiovanni G, Lama D. Coumarin anticoagulation during pregnancy in patients with mechani-cal valve prostheses. Eur J Cardiothorac Surg 1991;5:300304
140. Elkayam U, Gleicher N. Anticoagulation in pregnant women with artificial heart valves [letter]. N Engl J Med 1987;316:1663
141. Wang RY, Lee PK, Chow JS, Chen WW. Efficacy of low-dose, subcutaneously administered heparin in treatment of pregnant women with artificial heart valves. Med J Aust 1983:2:126128
142. Vital! E, Donatelli F, Quaini E, Groppelli G, Pellegrini A. Pregnancy in patients with mechanical prosthetic heart valves: our experience regarding 98 pregnancies in 57 patients. J Cardiovasc Surg 1986:27:221-227
143. Ginsberg JS, Barron WM. Pregnancy and prosthetic heart valves. Lancet 1994;344:1170-1172
144. Conti CR. Anticoagulation for prosthetic valves during pregnancy [editorial]. Clin Cardiol 1996;19:682
145. Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994;170:862-869
146. Ginsberg JS, Kowalchuck G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, et al. Heparin effect on bone density. Thromb Haemost 1990:64:286-289
147. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993:168:1265-1270
148. Prendergast BD, Banning AP, Hall RJ. Valvular heart disease: recommendations for investigation and management; summary of guidelines produced by a working group of the British Cardiac Society and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond 1996; 30:309-315
149. Oakley CM. Pregnancy and prosthetic heart valves [letter]. Lancet 1994;344:1643-1644
150. Bortolotti U, Milano A, Mazzucco A, Valfre C, Russo R, Valente M, et al. Pregnancy in patients with a porcine valve bioprosthesis. Am J Cardiol 1982;50:1051-1054
151. Badduke BR, Jamieson WR, Miyagishima RT, Munro AI, Gerein AN, MacNab J, et al. Pregnancy and childbearing in a population with biologic valvular prostheses. J Thorac Cardiovasc Surg 1991;102:179-186
152. McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983;103:325-327
153. Orme ML, Lewis PJ, de Swiet M, Serlin MJ, Sibeon R, Baty JD, et al. May mothers given warfarin breast-feed their infants? BMJ 1977:1:1564-1565
154. Tatro DS, editor. Drug Interaction Facts. St. Louis: Lippincott; 1990. pp 39-105
155. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Vancouver (WA): Applied Therapeutics; 1997
156. Brigden ML. When bleeding complicates oral anticoagulant therapy: how to anticipate, investigate, and treat. Postgrad Med 1995 Sep;98:153-154; 159-162; 164-165
157. HirshJ. Use of warfarin (coumarin). Heart Dis Stroke 1993;2:209216
158. Brigden ML. Oral anticoagulant therapy: newer indications and an improved method of monitoring. Postgrad Med 1992 Feb;91:285288; 293-296
159. Pedersen FM, Hamberg 0, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulation. J Intern Med 1991:229:517-520
160. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994:121:676683
161. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants: an update. Clin Pharmacokinet 1996;30:416444
162. Weser JK, Sellers E. Drug interactions with coumarin anticoagulants. 2. NEnglJMed 1971;285:547-558
163. Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand 1986;220:347-350
164. Kempin SJ. Warfarin resistance caused by broccoli [letter]. N EnglJ Med 1983;308:1229-1230
165. Udall JA. Drug interference with warfarin therapy. Clin Med 1970:77:20-25
166. O'Reilly RA. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. Am J Med Sei 1979;277:189194
167. O'Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med 1981:141:458459
168. Williams JR, Griffin JP, Parkins A. Effect of concomitantly administered drugs on the control of long term anticoagulant therapy. QJM 1976;45:63-73
169. Waris E. Effect of ethyl alcohol on some coagulation factors in man during anticoagulant therapy. Ann Med Exp Fenn 1963;41:4553
170. Kater RM, Roggin G, Tobon F, Zieve P, Iber FL. Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sei 1969:258:35-39